Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. New treatment approved for certain high-risk AML

    ... leaks into the skin and subcutaneous tissue from the intravenous infusion (extravasation). Women who are pregnant or breastfeeding should ...

    Article last updated 08/30/2017 - 7:18am.

  2. Intravenous infusion of allogeneic mesenchymal stromal cells in refractory or relapsed aplastic anemia

    ... 1/2 study to evaluate the addition of two to five weekly intravenous infusions of allogeneic unrelated non-human leukocyte ... stromal cells (MSCs) (median, 2.7 × 10(6) cells/kg/infusion; range, 1.3-4.5) to standard rabbit ATG and cyclosporine in nine ...

    Research Article last updated 12/09/2015 - 1:27pm.

  3. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... receive rigosertib 1800 mg per 24 h via 72-h continuous intravenous infusion administered every other week or best supportive care with or ...

    Research Article last updated 06/07/2016 - 11:10am.

  4. MDS Drug Therapy

    ... is given by injection under the skin or as an intravenous infusion (IV) where it is injected into your vein. It is given in a clinic ...

    Topic section last updated 03/10/2016 - 11:26pm.

  5. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

    ... (MDS) on a schedule of 15 mg/m(2) administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... purpose is to summarize the clinical activity and safety of intravenous (IV) rigosertib delivered by an external ambulatory infusion pump in patients with refractory anemia with excess ...

    Research Article last updated 05/22/2014 - 10:23am.

  7. SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

    ... with SL-401, which will be administered as a brief intravenous infusion for 3 consecutive days initially every 21 days for 4 cycles; every ...

    Clinical Trial last updated 06/06/2016 - 2:11pm.

  8. Health Care Team Players: Meet the Pharmacist

    ... dispensed (whether it is a pill, liquid or even intravenous infusion ), your pharmacist must check to see that the information provided ...

    Page last updated 05/29/2015 - 9:52am.

  9. Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

    ... filgrastim All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count ...

    Clinical Trial last updated 04/29/2016 - 9:56am.

  10. Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

    ... the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and ... Biological: CM-CS1 T-cell infusion Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion. ...

    Clinical Trial last updated 05/03/2016 - 9:53am.